Curemark initiates Phase III trial to evaluate CM-AT as a treatment for children with autism.

Curemark, LLC announced that the Bl�m Study, a Phase III clinical trial to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at 30 clinical sites across the United States. This 14-week, double-blind, randomized, placebo-controlled Phase III study is designed to determine if CM-AT may help improve core and non-core symptoms of Autism. CM-AT is designed to enhance protein digestion thereby potentially restoring the pool of essential amino acids. Essential amino acids play a critical role in the expression of several genes important to neurological function and serve as precursors to key neurotransmitters such as serotonin and dopamine.